Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug3260 | Raman analysis of saliva, characterization of the Raman database and building of the classification model Wiki | 0.71 |
| drug2823 | Passive Microwave Radiometry Wiki | 0.71 |
| drug3234 | RPH-104 80 mg Wiki | 0.71 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D045169 | Severe Acute Respiratory Syndrome NIH | 0.06 |
| D018352 | Coronavirus Infections NIH | 0.05 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There are 2 clinical trials
The primary objective of the study is to evaluate the efficacy and safety of a single dose of RPH-104 (80 mg) or OKZ (64 mg) compared to placebo in addition to standard therapy in patients with severe SARS-CoV-2 infection (COVID-19) at Day 15 of the study
Description: Proportion of patients, responded to the study therapy, in each of the treatment groups. The patient can be considered as the therapy responder, in case tocilizumab or sarilumab were not administered and there is an improvement of a clinical status at least by 1 point on a 6-points COVID-19 scale, where 1 point means most favorable outcome, 6 points means most undesirable outcome.
Measure: Proportion of patients, responded to the study therapy, in each of the treatment groups Time: Day 15Description: Changes of patients' clinical status on a 6 points ordinal scale over time
Measure: Changes of patients' clinical status on a 6 points ordinal scale over time Time: from Day 2 until Day 15, Day 29Description: Mortality rate over the follow-up period
Measure: Mortality rate over the follow-up period Time: from Day 1 until Day 29Description: Improvement of the patient's clinical status by at least 2 points on a 6-point ordinal scale in the absence of tocilizumab or sarilumab administration.
Measure: Improvement of the patient's clinical status by at least 2 points on a 6-point ordinal scale in the absence of tocilizumab or sarilumab administration. Time: on screening and then from Day 1 until Day 29Description: Proportion of patients received tocilizumab or sarilumab due to COVID-19
Measure: Proportion of patients received tocilizumab or sarilumab due to COVID-19 Time: from Day 1 until the Day 29Description: Proportion of patients having National Early Warning Score 2 (NEWS2) of ≤ 4 maintained for 2 consecutive days
Measure: Proportion of patients having National Early Warning Score 2 of ≤ 4 maintained for 2 consecutive days Time: from day 3 until day 15Description: Time to a NEWS2 of ≤ 2 maintained for two consecutive days
Measure: Time to a NEWS2 of ≤ 2 maintained for two consecutive days Time: from day 1 until day 15Description: Changes from baseline of cytokine storm surrogate markers: white blood counts, lymphocyte counts, neutrophils counts, CRP, ferritin (if applicable), D-dimer (if applicable)
Measure: Changes from baseline of cytokine storm surrogate markers: white blood counts, lymphocyte counts, neutrophils counts, C-Reactive protein (CRP), ferritin (if applicable), D-dimer (if applicable) Time: Day 2, Day 3, Day5, Day 7, Day 15Description: Mortality during an ICU stay, on days 7, 15, 29 of the study
Measure: Mortality during an ICU stay, on days 7, 15, 29 of the study Time: On Day 7, Day 15, Day 29Description: Time to increase of oxygen saturation SpO2 ≥ 94% n the absence of oxygen support maintained for two consecutive days
Measure: Time to increase of oxygen saturation SpO2 ≥ 94% n the absence of oxygen support maintained for two consecutive days Time: from Day 2 until Day 15Description: Changes of oxygenation index PaO2/FiO2 from baseline (if applicable) during hospitalization period
Measure: Changes of oxygenation index PaO2/FiO2 from baseline (if applicable) during hospitalization period Time: On Day 1 and from Day 2 until Day 15Description: Duration of ICU stay measured in days
Measure: Duration of ICU stay measured in days Time: from Day 2 until Day 15Description: Changes from baseline (if applicable) in severity of ARDS according to WHO criteria
Measure: Changes from baseline (if applicable) in severity of Acute Respiratory Distress Syndrome (ARDS) according to World Health Organization (WHO) criteria Time: from Day 1 until Day 15Description: Duration of mechanical ventilation and EMO (if applicable) measured in days
Measure: Duration of mechanical ventilation and Extracorporeal Membrane Oxygenation (EMO) (if applicable) measured in days Time: from Day 2 until Day 15Description: Duration of oxygen support (if applicable) measured in days
Measure: Duration of oxygen support (if applicable) measured in days Time: from Day 1 until Day 15Description: Proportion of patients having National Early Warning Score 2 of ≤ 2 maintained for 2 consecutive days
Measure: Proportion of patients having National Early Warning Score 2 of ≤ 2 maintained for 2 consecutive days Time: from day 3 until day 15Description: Time to a NEWS2 of ≤ 4 maintained for two consecutive days
Measure: Time to a NEWS2 of ≤ 4 maintained for two consecutive days Time: from day 1 until day 15Description: Time to improvement in severity of ARDS according to WHO criteria in one category changing from baseline (if applicable)
Measure: Time to improvement in severity of ARDS according to WHO criteria in one category changing from baseline (if applicable) Time: On Day 1 and from Day 2 until Day 15Description: Time to fever resolution i.e. setting of axillary body temperature <38 °C without antipyretics when measured for 2 consecutive days (if applicable)
Measure: Time to fever resolution i.e. setting of axillary body temperature <38 °C without antipyretics when measured for 2 consecutive days (if applicable) Time: from day 1 until day 15Description: Time to improvement of clinical status by 1 point on a 6-points COVID-19 scale
Measure: Time to improvement of clinical status by 1 point on a 6-points COVID-19 scale Time: from day 1 until day 29Description: Time to improvement of clinical status by 2 points on a 6-points COVID-19 scale
Measure: Time to improvement of clinical status by 2 points on a 6-points COVID-19 scale Time: from day 1 until day 29Description: Proportion of patients with the deterioration of clinical status by 1 point on a 6-points COVID-19 scale during the study
Measure: Proportion of patients with the deterioration of clinical status by 1 point on a 6-points COVID-19 scale during the study Time: from Day 1 until Day 29Description: Proportion of patients with the deterioration of clinical status by 1 point on a 6-points COVID-19 scale during the study, excluding the patients moved to the category 6, if applicable
Measure: Proportion of patients with the deterioration of clinical status by 1 point on a 6-points COVID-19 scale during the study, excluding the patients moved to the category 6, if applicable Time: from Day 1 until Day 29Description: Time to the deterioration of clinical status by 1 point on a 6-points COVID-19 scale during the study (if applicable)
Measure: Time to the deterioration of clinical status by 1 point on a 6-points COVID-19 scale during the study (if applicable) Time: from Day 1 until Day 29The primary objective of the study is to evaluate the efficacy of a single dose of OKZ (64 mg) vs placebo in addition to standard therapy in patients with severe SARS-CoV-2 infection (COVID-19) at Day 29.
Description: Difference between OKZ and placebo groups in the percentage of subjects with an improvement of at least 2 categories of the 5-points clinical status scale relative to baseline or in the "Not hospitalized" category. The points of the scale are: 1. Not hospitalized; 2.Hospitalized, not requiring supplemental oxygen; 3.Hospitalized, supplemental oxygen, spontaneous breathing;4. Hospitalized, mechanical ventilation (invasive/non-invasive) or extracorporeal membrane oxygenation (ECMO); 5. Death
Measure: Percentage of subjects achieving a change in their clinical status defined as improvement for at least 2 categories of the 5-points clinical status scale relative to baseline or in the "Not hospitalized" category Time: at Day 29Description: Subjects' clinical status distribution based on 5-point clinical status scale during the study
Measure: Subjects' clinical status distribution based on 5-point clinical status scale during the study Time: from Day 2 tо Day 15, Day 29, Day 60Description: 28-day case fatality rates
Measure: 28-day case fatality rates Time: from Day 1 to Day 29Description: Case fatality rates during the intensive care unit (ICU) stay at Days 7, 15, and 60
Measure: Case fatality rates during the intensive care unit (ICU) stay, at Days 7, 15, and 60 Time: from Day 1 to Day 60Description: Duration of oxygen support (if applicable)
Measure: Duration of oxygen support Time: From Day 1 to Day 60Description: The time period until SpO2 ≥ 94% at ambient air during 2 consequence days is reached
Measure: The time period until SpO2 ≥ 94% at ambient air during 2 consequence days is reached Time: from Day 2 to Day 60Description: Changes of oxygenation index PaO2/FiO2 from baseline (if applicable)
Measure: Changes of oxygenation index PaO2/FiO2 from baseline Time: from Day 2 to Day 60Description: Duration of oxygen support (if applicable), in days
Measure: Duration of oxygen support (if applicable) Time: from Day 1 to Day 60Description: Duration of mechanical ventilation and/or ECMO (if applicable), in days
Measure: Duration of mechanical ventilation and/or ECMO (if applicable) Time: from Day 1 to Day 60Description: Duration of ICU stay (if applicable)
Measure: Duration of ICU stay (if applicable) Time: from Day 1 to Day 60Description: Changes from baseline of COVID-19 cytokine storm surrogate marker: white blood count
Measure: Changes from baseline of COVID-19 cytokine storm surrogate marker: white blood count Time: from Day 2 and until the end of hospitalization, Day 29 as a maximumDescription: Changes from baseline of COVID-19 cytokine storm surrogate marker: lymphocyte counts
Measure: Changes from baseline of COVID-19 cytokine storm surrogate marker: lymphocyte count Time: from Day 2 and until the end of hospitalization, Day 29 as a maximumDescription: Changes from baseline of COVID-19 cytokine storm surrogate marker: neutrophils count
Measure: Changes from baseline of COVID-19 cytokine storm surrogate marker: neutrophils count Time: from Day 2 and until the end of hospitalization, Day 29 as a maximumDescription: Changes from baseline of COVID-19 cytokine storm surrogate marker: C-reactive protein (CRP)
Measure: Changes from baseline of COVID-19 cytokine storm surrogate marker: C-reactive protein (CRP) Time: from Day 2 and until the end of hospitalization, Day 29 as a maximumDescription: Changes from baseline of COVID-19 cytokine storm surrogate marker: ferritin
Measure: Changes from baseline of COVID-19 cytokine storm surrogate marker: ferritin Time: from Day 2 and until the end of hospitalization, Day 29 as a maximumDescription: Changes from baseline of COVID-19 cytokine storm surrogate marker:D-dimer
Measure: Changes from baseline of COVID-19 cytokine storm surrogate marker:D-dimer Time: from Day 2 and until the end of hospitalization, Day 29 as a maximumDescription: Changes from baseline of COVID-19 cytokine storm surrogate marker:platelets
Measure: Changes from baseline of COVID-19 cytokine storm surrogate marker:platelets Time: from Day 2 and until the end of hospitalization, Day 29 as a maximumDescription: Changes from baseline of COVID-19 cytokine storm surrogate marker: triglycerides
Measure: Changes from baseline of COVID-19 cytokine storm surrogate marker: triglycerides Time: from Day 2 and until the end of hospitalization, Day 29 as a maximumDescription: The time period until National Early Warning Score 2 (NEWS2) ≤ 2 during 2 consequent days is reached
Measure: The time period until National Early Warning Score 2 (NEWS2) ≤ 2 during 2 consequent days is reached Time: from Day 1 and until the end of hospitalization, Day 29 as a maximumDescription: The time period until National Early Warning Score 2 (NEWS2) ≤ 4 during 2 consequent days is reached
Measure: The time period until National Early Warning Score 2 (NEWS2) ≤ 4 during 2 consequent days is reached Time: from Day 1 and until the end of hospitalization, Day 29 as a maximumAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports